Pathological Analysis of False-Positive Samples in Photodynamic Diagnosis of Bladder Cancer According to a History of Intravesical Bacillus Calmette-Gu��rin Therapy.

Takeshi Sano, Chisato Ohe, Takahiro Nakamoto, Takashi Yoshida, Hisanori Taniguchi, Masaaki Yanishi, Hidefumi Kinoshita
Author Information
  1. Takeshi Sano: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. ORCID
  2. Chisato Ohe: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
  3. Takahiro Nakamoto: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
  4. Takashi Yoshida: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
  5. Hisanori Taniguchi: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. ORCID
  6. Masaaki Yanishi: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
  7. Hidefumi Kinoshita: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.

Abstract

OBJECTIVES: To demonstrate the diagnostic performance of photodynamic diagnosis (PDD) for bladder cancer using oral 5-aminolaevulinic acid in patients with or without a history of intravesical Bacillus Calmette-Gu��rin (BCG) therapy, and to investigate the potential causes of false-positive results.
METHODS: This retrospective study included 110 patients with suspected non-muscle-invasive bladder cancer who underwent PDD. Among them, 80 patients had no history of BCG therapy (BCG-na��ve group) and 30 had received BCG therapy (BCG group). Pathological examination of false-positive and true-negative PDD samples was performed.
RESULTS: In the BCG-na��ve group, 215 samples were PDD-positive, of which 53 (24.7%) showed no malignancy. In the BCG group, 94 samples were PDD-positive, of which 51 (54.3%) showed no malignancy. The sensitivity, specificity, positive predictive value, and negative predictive value of PDD in the BCG-na��ve versus BCG group were 70.1 versus 76.8, 82.6 versus 56.0, 75.3 versus 45.7, and 78.5 versus 83.3, respectively. Only six of 100 samples (6%) with false-positive PDD results showed precancerous findings. Irrespective of whether patients had received intravesical BCG therapy, >���90% of the samples with false positivity in PDD showed reactive changes, whereas 22 of 95 samples (23.2%) with true negativity in PDD showed reactive changes (p���<���0.0001).
CONCLUSIONS: Both the specificity and positive predictive value of PDD were lower in the BCG group than in the BCG-na��ve group. In most false-positive PDD samples, reactive changes, rather than precancerous findings, were observed-even in the BCG-na��ve group.

Keywords

References

  1. H. Matsumoto, K. Shiraishi, H. Azuma, et al., ���Clinical Practice Guidelines for Bladder Cancer 2019 Update by the Japanese Urological Association: Summary of the Revision,��� International Journal of Urology 27 (2020): 702���709.
  2. M. Babjuk, M. Burger, O. Capoun, et al., ���European Association of Urology Guidelines on Non���Muscle���Invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ),��� European Urology 81 (2022): 75���94.
  3. J. Holzbeierlein, B. R. Bixler, D. I. Buckley, et al., ���Treatment of Non���Metastatic Muscle���Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024),��� Journal of Urology 212 (2024): 3���10.
  4. T. W. Flaig, P. E. Spiess, M. Abern, et al., ���NCCN Guidelines�� Insights: Bladder Cancer, Version 2.2022,��� Journal of the National Comprehensive Cancer Network 20 (2022): 866���878.
  5. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. B��hle, and J. Palou���Redorta, ���EAU Guidelines on Non���Muscle���Invasive Urothelial Carcinoma of the Bladder,��� European Urology 54 (2008): 303���314.
  6. R. J. Sylvester, O. Rodr��guez, V. Hern��ndez, et al., ���European Association of Urology (EAU) Prognostic Factor Risk Groups for Non���Muscle���Invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update From the EAU NMIBC Guidelines Panel,��� European Urology 79 (2021): 480���488.
  7. C. R. Ritch, M. C. Velasquez, D. Kwon, et al., ���Use and Validation of the AUA/SUO Risk Grouping for Non���Muscle Invasive Bladder Cancer in a Contemporary Cohort,��� Journal of Urology 203 (2020): 505���511.
  8. I. Kausch, M. Sommerauer, F. Montorsi, et al., ���Photodynamic Diagnosis in Non���Muscle���Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies,��� European Urology 57 (2010): 595���606.
  9. M. Burger, H. B. Grossman, M. Droller, et al., ���Photodynamic Diagnosis of Non���Muscle���Invasive Bladder Cancer With Hexaminolevulinate Cystoscopy: A Meta���Analysis of Detection and Recurrence Based on Raw Data,��� European Urology 64 (2013): 846���854.
  10. R. Chou, S. Selph, D. I. Buckley, et al., ���Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta���Analysis,��� Journal of Urology 197 (2017): 548���558.
  11. T. Kawai, H. Matsuyama, K. Kobayashi, et al., ���Photodynamic Diagnosis���Assisted Transurethral Resection of Bladder Tumor for High���Risk Non���Muscle Invasive Bladder Cancer Improves Intravesical Recurrence���Free Survival (BRIGHT Study),��� International Journal of Urology 31 (2024): 906���912.
  12. R. Taoka, Y. Matsuoka, M. Yamasaki, et al., ���Photodynamic Diagnosis���Assisted Transurethral Resection Using Oral 5���Aminolevulinic Acid Decreases Residual Cancer and Improves Recurrence���Free Survival in Patients With Non���muscle���Invasive Bladder Cancer,��� Photodiagnosis and Photodynamic Therapy 38 (2022): 102838.
  13. P. Maisch, A. Koziarz, J. Vajgrt, V. Narayan, M. H. Kim, and P. Dahm, ���Blue vs. White Light for Transurethral Resection of Non���Muscle���Invasive Bladder Cancer: An Abridged Cochrane Review,��� BJU International 130 (2022): 730���740.
  14. K. Inoue, H. Fukuhara, T. Shimamoto, et al., ���Comparison Between Intravesical and Oral Administration of 5���Aminolevulinic Acid in the Clinical Benefit of Photodynamic Diagnosis for Non���Muscle Invasive Bladder Cancer,��� Cancer 118 (2012): 1062���1074.
  15. T. Bach, P. J. Bastian, A. Blana, et al., ���Optimised Photodynamic Diagnosis for Transurethral Resection of the Bladder (TURB) in German Clinical Practice: Results of the Noninterventional Study OPTIC III,��� World Journal of Urology 35, no. 5 (2017): 737���744, https://doi.org/10.1007/s00345���016���1925���0.
  16. H. Matsuyama, Y. Yamamoto, K. Nagao, C. Ohmi, S. Sakano, and K. Sasaki, ���Cytogenetic Analysis of False���Positive Mucosa by Photodynamic Diagnosis Using 5���Aminolevulinic Acid���Possible Existence of Premalignant Genomic Alterations Examined by In Vitro Experiment,��� Oncology 76 (2009): 118���125.
  17. M. Kriegmair, R. Baumgartner, R. Kn��chel, H. Stepp, F. Hofst��dter, and A. Hofstetter, ���Detection of Early Bladder Cancer by 5���Aminolevulinic Acid Induced Porphyrin Fluorescence,��� Journal of Urology 155 (1996): 105���109.
  18. E. R. Ray, K. Chatterton, M. S. Khan, et al., ���Hexylaminolaevulinate Fluorescence Cystoscopy in Patients Previously Treated With Intravesical Bacille Calmette���Gu��rin,��� BJU International 105 (2010): 789���794.
  19. R. O. Draga, M. C. Grimbergen, E. T. Kok, T. N. Jonges, C. F. van Swol, and J. L. Bosch, ���Photodynamic Diagnosis (5���Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette���Gu��rin Immunotherapy and Mitomycin C Intravesical Therapy,��� European Urology 57 (2010): 655���660.
  20. Y. Fradet, H. B. Grossman, L. Gomella, et al., ���A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study,��� Journal of Urology 178 (2007): 68���73.
  21. G. P. Paner, S. C. Smith, A. Hartmann, P. K. Agarwal, E. Comp��rat, and M. B. Amin, ���Flat Intraurothelial Lesions of the Urinary Bladder���Do Hyperplasia, Dysplasia, and Atypia of Unknown Significance Need to Exist as Diagnostic Entities? And How to Handle in Routine Clinical Practice,��� Modern Pathology 35 (2022): 1296���1305.
  22. T. Nohara, A. Takimoto, R. Shinzawa, et al., ���Comprehensive Analysis of Perioperative Hypotension in Photodynamic Diagnosis���Assisted Transurethral Resection of Bladder Tumor With 5���Aminolevulinic Acid,��� International Journal of Urology 31 (2024): 891���898.
  23. Y. Ishikawa, H. Tanaka, M. Fujiwara, et al., ���Incidence and Predictors of Intraoperative Hypotension During Transurethral Bladder Tumor Resection With Oral 5���Aminolevulinic Acid,��� International Journal of Urology 31 (2024): 238���244.
  24. R. Taoka, K. Yamada, Y. Sawanobori, et al., ���Oral 5���Aminolevulinic Acid Administration Before Transurethral Resection of Bladder Tumor Induces Perioperative Nausea and Vomiting,��� Photodiagnosis and Photodynamic Therapy 43 (2023): 103707.
  25. Y. Nakai, K. Inoue, T. Tsuzuki, et al., ���Oral 5���Aminolevulinic Acid���Mediated Photodynamic Diagnosis Using Fluorescence Cystoscopy for Non���Muscle���Invasive Bladder Cancer: A Multicenter Phase III Study,��� International Journal of Urology 25 (2018): 723���729.
  26. S. Yamamoto, H. Fukuhara, T. Karashima, and K. Inoue, ���Real���World Experience With 5���Aminolevulinic Acid for the Photodynamic Diagnosis of Bladder Cancer: Diagnostic Accuracy and Safety,��� Photodiagnosis and Photodynamic Therapy 32 (2020): 101999.
  27. P. Jichlinski, M. Forrer, J. Mizeret, et al., ���Clinical Evaluation of a Method for Detecting Superficial Surgical Transitional Cell Carcinoma of the Bladder by Light���Induced Fluorescence of Protoporphyrin IX Following the Topical Application of 5���Aminolevulinic Acid: Preliminary Results,��� Lasers in Surgery and Medicine 20 (1997): 402���408.
  28. M. C. Grimbergen, C. F. van Swol, T. G. Jonges, T. A. Boon, and R. J. van Moorselaar, ���Reduced Specificity of 5���ALA Induced Fluorescence in Photodynamic Diagnosis of Transitional Cell Carcinoma After Previous Intravesical Therapy,��� European Urology 44 (2003): 51���56.
  29. P. G. Pavlidakey, G. T. MacLennan, and H. B. Goldman, ���Nephrogenic Adenoma of the Bladder,��� Journal of Urology 184 (2010): 2535���2536.
  30. S. Jallad, S. Goubet, A. Symes, T. Larner, and P. Thomas, ���Prognostic Value of Inflammation or Granuloma After Intravesival BCG in Non���Muscle���Invasive Bladder Cancer,��� BJU International 113 (2014): E22���E27.

Word Cloud

Created with Highcharts 10.0.0PDDBCGgroupsamplesBCG-na��veshowedversuspatientstherapyfalse-positivebladderpositivepredictivevaluereactivechangesphotodynamicdiagnosiscanceracidhistoryintravesicalBacillusCalmette-Gu��rinresultsreceivedPathologicalPDD-positivemalignancyspecificity3precancerousfindingsfalseOBJECTIVES:demonstratediagnosticperformanceusingoral5-aminolaevulinicwithoutinvestigatepotentialcausesMETHODS:retrospectivestudyincluded110suspectednon-muscle-invasiveunderwentAmong8030examinationtrue-negativeperformedRESULTS:21553247%9451543%sensitivitynegative7017688265607545778583respectivelysix1006%Irrespectivewhether>���90%positivitywhereas2295232%truenegativityp���<���00001CONCLUSIONS:lowerratherobserved-evenAnalysisFalse-PositiveSamplesPhotodynamicDiagnosisBladderCancerAccordingHistoryIntravesicalTherapy5���aminolevulinichydrochloridecarcinomapathologicalanalysis

Similar Articles

Cited By

No available data.